DarioHealth’s fair value estimate has been reduced, driven by a substantial drop in future P/E and a higher discount rate, resulting in the analyst price target falling from $39.25 to $25.50.
What's in the News
- Launched five new contracts with self-insured employers for Dario’s full cardiometabolic suite, demonstrating improvements in diabetes (1.4% eHbA1c reduction), prediabetes (10% BMI reduction), and hypertension (38% users lowered stage).
- Approved and authorized a reverse stock split at a ratio of between 2:1 and 25:1; subsequently executed a 1-for-20 reverse stock split.
- Shareholders ratified Kesselman & Kesselman (PwC) as independent auditor for fiscal year ending December 31, 2025.
- Entered a strategic commercial agreement with GreenKey Health to offer an integrated care program targeting sleep apnea, behavioral health, and cardiometabolic conditions to payers and self-insured employers nationwide.
- Presented four studies at the ADA Scientific Sessions, highlighting dramatic eA1c improvements in GLP-1 users, sustained outcomes post-medication, and 89% AI-driven accuracy in predicting next-month blood glucose levels.
Valuation Changes
Summary of Valuation Changes for DarioHealth
- The Consensus Analyst Price Target has significantly fallen from $39.25 to $25.50.
- The Future P/E for DarioHealth has significantly fallen from 27.59x to 18.35x.
- The Discount Rate for DarioHealth has risen from 11.45% to 12.32%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.